ClinicalTrials.Veeva

Menu

Neurocognition After Radiotherapy in CNS- and Skull-base Tumors (NARCiS)

U

Universitaire Ziekenhuizen KU Leuven

Status

Enrolling

Conditions

Glioma
Meningioma
Brain Tumor
Pituitary Adenoma
Cognition
Magnetic Resonance Imaging

Treatments

Behavioral: Neurocognitive tests: WAIS digit span, HVLT-R, COWAT, MOCA, WAIS digit symbol substitution, TMT A&B, Stroop Color Word Test
Behavioral: Questionnaires: EORTC QLQ C30 & BN20, STAI, CFQ, BDI-II, BRIEF-A, FACIT-F, PSQI
Diagnostic Test: MRI
Other: Toxicity scoring

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The goal of this multicenter prospective longitudinal study is to study the long-term impact of multimodal treatment (chemotherapy, radiotherapy and surgery) in adult brain and base of skull tumors on neurocognitive functioning.

All included patients will complete a self-report inventory (subjective cognitive functioning, QoL, confounders), a cognitive test battery, an advanced MR at multiple timepoints. Moreover, toxicity will be scored according to the CTCAEv5.0 in these patients over time.

Full description

This study will combine MR imaging techniques together with elaborate neuropsychological assessments and RT dosimetry in 120 patients who will be examined baseline (before RT) and followed longitudinally after RT.

The first objective is to build an NTCP model for neurocognitive decline after RT (for each cognitive domain separately), linking dose-volume parameters to structures within the brain susceptible to neurological damage and neurocognitive decline after radiotherapy. These NTCP models can be used to make predictions on neurocognitive decline in future primary brain tumour patients receiving cranial RT.

The second objective is to evaluate dose-dependent neurocognitive decline. In particular, the investigators will assess:

  • Prevalence and severity of neurocognitive decline after RT for all cognitive domains
  • Brain structures or functional brain connections important in neurocognitive functioning (based on dedicated MRI).
  • Dose-dependencies of specific neurocognitive skills after RT in adult brain tumour patients
  • Correlations between RT dosimetry and early brain changes (MRI)

Enrollment

120 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients (≥ 18 years at the time of diagnosis) with a primary brain or base of skull tumour, who are amenable for conventionally fractionated radiotherapy (photon or proton irradiation)

Exclusion criteria

  • Patients with tumours with poor prognostic characteristics:

    • Incompletely resected IDH-wild-type glioma
    • Completely resected IDH-wild-type and MGMT-promotor unmethylated glioma
    • grade III meningioma
    • H3K27M+ midline glioma
  • Patients with tumours requiring craniospinal irradiation (CSI)/whole ventricular irradiation (WVI)

  • Hypofractionated/stereotactic radiation (fraction sizes > 2 Gy per fraction)

  • Inability to perform the cognitive tests or self-report inventories because of motor/sensory deficits or insufficient Dutch language proficiency

  • Mental retardation documented before diagnosis

  • Pre-diagnosis/pre-existing psychiatric diagnosis resulting in cognitive deficits like psychoses, neurodevelopmental disorders (autism/learning disorders)

  • Relapse previously treated by chemo and/or radiation therapy

  • Genetic syndrome (e.g. Down)

  • Unable to perform MR imaging (claustrophobia, metallic implants like pacemaker/ICD/neurostimulator)

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

120 participants in 1 patient group

Primary brain and skull-base tumors
Other group
Description:
Primary brain and skull-base tumors who are amenable for radiotherapy (photon or proton therapy) will all be examined with neurocognitive tests, questionnaires and advanced MR imaging
Treatment:
Diagnostic Test: MRI
Behavioral: Neurocognitive tests: WAIS digit span, HVLT-R, COWAT, MOCA, WAIS digit symbol substitution, TMT A&B, Stroop Color Word Test
Other: Toxicity scoring
Behavioral: Questionnaires: EORTC QLQ C30 & BN20, STAI, CFQ, BDI-II, BRIEF-A, FACIT-F, PSQI

Trial contacts and locations

3

Loading...

Central trial contact

Maarten Lambrecht, MD PhD; Laurien De Roeck, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems